Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On June 15, 2022, Advent Technologies Holdings, Inc. (the "Company") received a
letter from the staff of the Listing Qualifications Department of the Nasdaq
Stock Market (the "Staff") stating that due to the resignation of Katrina Fritz
as a director from the Company's board of directors (the "Board") on May 27,
2022, which was previously reported in a current report on Form 8-K filed with
the Securities and Exchange Commission on June 3, 2022, the Company no longer
complies with Nasdaq Listing Rule 5605, which requires that a majority of the
Board be independent. In accordance with Nasdaq Listing Rule 5605(b)(1)(A),
Nasdaq will provide the Company a cure period in order to regain compliance as
follows: (i) until the earlier of the Company's next annual stockholders'
meeting or May 27, 2023; or (ii) if the Company's next annual stockholders'
meeting is held before November 23, 2022, then the Company must evidence
compliance no later than November 23, 2022 (the "Cure Period"). If the Company
fails to regain compliance within the Cure Period, the Nasdaq Listing Rules
require the Staff to provide written notification to the Company that its
securities will be delisted.
The Company is actively engaged in efforts to regain compliance with the
majority independent board requirement set forth in Nasdaq Listing Rule 5605 and
plans to regain compliance within the Cure Period provided by Nasdaq.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses